Abstract：
UNASSIGNED: Invasive meningococcal disease (IMD) is potentially fatal and associated with severe sequelae among survivors. It is preventable by several vaccines, including meningococcal vaccines targeting the most common disease-causing serogroups (A, B, C, W, Y). The meningococcal ACWY tetanus toxoid conjugate vaccine (MenACWY-TT [Nimenrix]) is indicated from 6 weeks of age in the European Union and >50 additional countries.
UNASSIGNED: Using PubMed, Google Scholar, ClinicalTrials.gov and ad hoc searches for publications to June 2023, we review evidence of antibody persistence for up to 10 years after primary vaccination and up to 6 years after MenACWY-TT revaccination. We also review global MenACWY revaccination recommendations and real-world impact of vaccination policies, focusing on how these data can be considered alongside antibody persistence data to inform future IMD prevention strategies.
UNASSIGNED: Based on clear evidence that immunogenicity data (demonstrated antibody titers above established correlates of protection) are correlated with real-world effectiveness, long-term persistence of antibodies after MenACWY-TT vaccination suggests continuing protection against IMD. Optimal timing of primary and subsequent vaccinations is critical to maximize direct and indirect protection. Recommending bodies should carefully consider factors such as age at vaccination and long-term immune responses associated with the specific vaccine being used.
UNASSIGNED: Using PubMed, Google Scholar, ClinicalTrials.gov and ad hoc searches for publications to June 2023, we review evidence of antibody persistence for up to 10 years after primary vaccination and up to 6 years after MenACWY-TT revaccination. We also review global MenACWY revaccination recommendations and real-world impact of vaccination policies, focusing on how these data can be considered alongside antibody persistence data to inform future IMD prevention strategies.
UNASSIGNED: Based on clear evidence that immunogenicity data (demonstrated antibody titers above established correlates of protection) are correlated with real-world effectiveness, long-term persistence of antibodies after MenACWY-TT vaccination suggests continuing protection against IMD. Optimal timing of primary and subsequent vaccinations is critical to maximize direct and indirect protection. Recommending bodies should carefully consider factors such as age at vaccination and long-term immune responses associated with the specific vaccine being used.
摘要：
■侵袭性脑膜炎球菌病（IMD）可能致命，并与幸存者的严重后遗症有关。它可以通过几种疫苗来预防，包括针对最常见的致病血清群的脑膜炎球菌疫苗(A，B,C,W,Y).脑膜炎球菌ACWY破伤风类毒素结合疫苗（MenACWY-TT[Nimenrix]）在欧盟和>50个其他国家从6周龄开始。
■使用PubMed，谷歌学者，ClinicalTrials.gov和特设搜索到2023年6月的出版物，我们回顾了初次疫苗接种后长达10年的抗体持久性和MenACWY-TT再接种后长达6年的证据。我们还审查了全球MenACWY再接种建议和疫苗接种政策的现实世界影响。重点关注如何将这些数据与抗体持久性数据一起考虑，以告知未来的IMD预防策略。
■基于明确的证据表明，免疫原性数据（证明抗体滴度高于已确定的保护相关性）与现实世界的有效性相关，MenACWY-TT疫苗接种后抗体的长期持续存在表明,针对IMD的持续保护.初次和后续疫苗接种的最佳时机对于最大程度地提供直接和间接保护至关重要。推荐机构应仔细考虑诸如接种疫苗的年龄和与所使用的特定疫苗相关的长期免疫应答等因素。
■使用PubMed，谷歌学者，ClinicalTrials.gov和特设搜索到2023年6月的出版物，我们回顾了初次疫苗接种后长达10年的抗体持久性和MenACWY-TT再接种后长达6年的证据。我们还审查了全球MenACWY再接种建议和疫苗接种政策的现实世界影响。重点关注如何将这些数据与抗体持久性数据一起考虑，以告知未来的IMD预防策略。
■基于明确的证据表明，免疫原性数据（证明抗体滴度高于已确定的保护相关性）与现实世界的有效性相关，MenACWY-TT疫苗接种后抗体的长期持续存在表明,针对IMD的持续保护.初次和后续疫苗接种的最佳时机对于最大程度地提供直接和间接保护至关重要。推荐机构应仔细考虑诸如接种疫苗的年龄和与所使用的特定疫苗相关的长期免疫应答等因素。
